Compare Stocks: BNXTF, VANI, CPIX, and NRXP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNXTF BioNxt Solutions	$0.23 +2.4%	$0.24	$0.14 ▼ $0.80	$31.12M	0.7	222 shs	200 shs
CPIX Cumberland Pharmaceuticals	$7.96 +2.2%	$6.55	$1.85 ▼ $8.45	$116.72M	0.08	142,899 shs	79,334 shs
NRXP NRx Pharmaceuticals	$3.40 +1.5%	$3.85	$1.62 ▼ $5.05	$121.37M	2.18	1.17 million shs	1.17 million shs
VANI Vivani Medical	$1.39 -1.4%	$1.29	$0.92 ▼ $1.92	$121.59M	2.35	207,210 shs	53,826 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNXTF BioNxt Solutions	+2.40%	+8.93%	-6.27%	-33.10%	-66.02%
CPIX Cumberland Pharmaceuticals	+2.18%	+2.08%	+34.23%	+64.12%	+180.28%
NRXP NRx Pharmaceuticals	+1.49%	+11.48%	-18.85%	+15.25%	+46.55%
VANI Vivani Medical	-1.42%	-0.71%	+2.21%	+19.83%	+10.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNXTF BioNxt Solutions	$0.23 +2.4%	$0.24	$0.14 ▼ $0.80	$31.12M	0.7	222 shs	200 shs
CPIX Cumberland Pharmaceuticals	$7.96 +2.2%	$6.55	$1.85 ▼ $8.45	$116.72M	0.08	142,899 shs	79,334 shs
NRXP NRx Pharmaceuticals	$3.40 +1.5%	$3.85	$1.62 ▼ $5.05	$121.37M	2.18	1.17 million shs	1.17 million shs
VANI Vivani Medical	$1.39 -1.4%	$1.29	$0.92 ▼ $1.92	$121.59M	2.35	207,210 shs	53,826 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNXTF BioNxt Solutions	+2.40%	+8.93%	-6.27%	-33.10%	-66.02%
CPIX Cumberland Pharmaceuticals	+2.18%	+2.08%	+34.23%	+64.12%	+180.28%
NRXP NRx Pharmaceuticals	+1.49%	+11.48%	-18.85%	+15.25%	+46.55%
VANI Vivani Medical	-1.42%	-0.71%	+2.21%	+19.83%	+10.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNXTF BioNxt Solutions	0.00	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	1.00	Sell	N/A	N/A
NRXP NRx Pharmaceuticals	2.50	Moderate Buy	$34.50	914.71% Upside
VANI Vivani Medical	2.25	Hold	$3.75	169.78% Upside

Current Analyst Ratings Breakdown

Latest BNXTF, VANI, CPIX, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00
8/5/2026	NRXP NRx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	CPIX Cumberland Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/23/2026	VANI Vivani Medical	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/23/2026	VANI Vivani Medical	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/9/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNXTF BioNxt Solutions	$20K	1,593.61	N/A	N/A	($0.05) per share	-4.68
CPIX Cumberland Pharmaceuticals	$44.52M	2.68	$0.37 per share	21.24	$1.64 per share	4.85
NRXP NRx Pharmaceuticals	$1.23M	100.15	N/A	N/A	($0.54) per share	-6.30
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNXTF BioNxt Solutions	-$5.03M	-$0.05	N/A	N/A	N/A	N/A	N/A	-1,173.20%	N/A
CPIX Cumberland Pharmaceuticals	-$2.84M	-$0.71	N/A	N/A	N/A	-34.40%	-26.77%	-8.97%	N/A
NRXP NRx Pharmaceuticals	-$28.62M	-$1.09	N/A	5.76	N/A	N/A	N/A	-202.92%	8/17/2026 (Estimated)
VANI Vivani Medical	-$26.61M	-$0.40	N/A	N/A	N/A	N/A	-264.04%	-79.85%	8/12/2026 (Estimated)

Latest BNXTF, VANI, CPIX, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.09	N/A	N/A	N/A	$1.33 million	N/A
8/12/2026	Q2 2026	VANI Vivani Medical	-$0.08	N/A	N/A	N/A	N/A	N/A
8/4/2026	Q2 2026	CPIX Cumberland Pharmaceuticals	-$0.13	-$0.20	-$0.07	-$0.29	$8.50 million	$0.17 million
5/29/2026	Q1 2026	BNXTF BioNxt Solutions	N/A	-$0.01	N/A	-$0.02	N/A	N/A
5/15/2026	Q1 2026	NRXP NRx Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	$19.43 million	$1.07 million
5/13/2026	Q1 2026	VANI Vivani Medical	-$0.08	-$0.08	N/A	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNXTF BioNxt Solutions	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Latest BNXTF, VANI, CPIX, and NRXP Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/13/2026	CPIX Cumberland Pharmaceuticals		$1.50			7/23/2026	7/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNXTF BioNxt Solutions	N/A	0.01	0.01
CPIX Cumberland Pharmaceuticals	0.25	0.95	0.79
NRXP NRx Pharmaceuticals	N/A	0.29	0.29
VANI Vivani Medical	N/A	3.18	3.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNXTF BioNxt Solutions	N/A
CPIX Cumberland Pharmaceuticals	15.51%
NRXP NRx Pharmaceuticals	4.27%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
BNXTF BioNxt Solutions	N/A
CPIX Cumberland Pharmaceuticals	42.07%
NRXP NRx Pharmaceuticals	6.40%
VANI Vivani Medical	53.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNXTF BioNxt Solutions	20	136.09 million	N/A	Not Optionable
CPIX Cumberland Pharmaceuticals	80	14.98 million	8.68 million	Optionable
NRXP NRx Pharmaceuticals	2	36.23 million	33.91 million	Optionable
VANI Vivani Medical	20	86.24 million	40.27 million	Optionable

BNXTF, VANI, CPIX, and NRXP Headlines

Recent News About These Companies

Vivani Medical (VANI) Projected to Release Earnings on Wednesday

August 10 at 4:26 AM | americanbankingnews.com

Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial

August 6, 2026 | finance.yahoo.com

ClearOne (CLRO) stock soars over 98% after hours: Here's what you need to know

August 6, 2026 | msn.com

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic ...

August 6, 2026 | finance.yahoo.com

Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial

August 6, 2026 | tipranks.com

Vivani Medical (VANI) to Announce Earnings on Wednesday

August 5, 2026 | marketbeat.com

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

July 15, 2026 | marketbeat.com

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

July 14, 2026 | globenewswire.com

Next Frontier In Weight Loss? New Implant Looks To Lock In GLP-1 Results

July 14, 2026 | msn.com

The next GLP-1 bet? Implant draws Novo interest

July 13, 2026 | beckershospitalreview.comB

Vivani Medical

July 13, 2026 | fool.com

Weight-loss implant could one day replace Ozempic injections

July 12, 2026 | msn.com

Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal

July 9, 2026 | finance.yahoo.com

Vivani Medical signs agreement with Novo Nordisk to evaluate NPM-139

July 9, 2026 | pharmabiz.comP

Ozempic & Wegovy maker to evaluate long-acting GLP-1 implant that could last up to a year

July 9, 2026 | msn.com

Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical

July 7, 2026 | fiercebiotech.comF

Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant

July 7, 2026 | finance.yahoo.com

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

July 7, 2026 | globenewswire.com

Vivani strikes reverse-merger agreement with ClearOne for BCI business

July 3, 2026 | finance.yahoo.com

ClearOne to Merge With Vivani Medical Subsidiary Cortigent

July 2, 2026 | marketwatch.com

Vivani to sell neurotech subsidiary Cortigent to ClearOne

July 2, 2026 | massdevice.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNXTF, VANI, CPIX, and NRXP Company Descriptions

BioNxt Solutions OTCMKTS:BNXTF

$0.23 +0.01 (+2.40%)

As of 08/11/2026 11:52 AM Eastern

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Cumberland Pharmaceuticals NASDAQ:CPIX

$7.96 +0.17 (+2.18%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$7.95 -0.01 (-0.13%)

As of 08/11/2026 07:34 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

NRx Pharmaceuticals NASDAQ:NRXP

$3.40 +0.05 (+1.49%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$3.42 +0.02 (+0.44%)

As of 08/11/2026 07:34 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Vivani Medical NASDAQ:VANI

$1.39 -0.02 (-1.42%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.36%)

As of 08/11/2026 07:58 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNXTF, VANI, CPIX, and NRXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNXTF, VANI, CPIX, and NRXP Earnings

Compare Dividends

Latest BNXTF, VANI, CPIX, and NRXP Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNXTF, VANI, CPIX, and NRXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNXTF, VANI, CPIX, and NRXP Company Descriptions

BioNxt Solutions OTCMKTS:BNXTF

Cumberland Pharmaceuticals NASDAQ:CPIX

NRx Pharmaceuticals NASDAQ:NRXP

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNXTF, VANI, CPIX, and NRXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNXTF, VANI, CPIX, and NRXP Earnings

Compare Dividends

Latest BNXTF, VANI, CPIX, and NRXP Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNXTF, VANI, CPIX, and NRXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNXTF, VANI, CPIX, and NRXP Company Descriptions

BioNxt Solutions OTCMKTS:BNXTF

Cumberland Pharmaceuticals NASDAQ:CPIX

NRx Pharmaceuticals NASDAQ:NRXP

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools